Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 30
Filter
Add more filters










Publication year range
1.
Cell Death Differ ; 23(10): 1615-27, 2016 10.
Article in English | MEDLINE | ID: mdl-27258787

ABSTRACT

Mutations in the p53 tumor-suppressor gene are prevalent in human cancers. The majority of p53 mutations are missense, which can be classified into contact mutations (that directly disrupts the DNA-binding activity of p53) and structural mutations (that disrupts the conformation of p53). Both of the mutations can disable the normal wild-type (WT) p53 activities. Nevertheless, it has been amply documented that small molecules can rescue activity from mutant p53 by restoring WT tumor-suppressive functions. These compounds hold promise for cancer therapy and have now entered clinical trials. In this study, we show that cruciferous-vegetable-derived phenethyl isothiocyanate (PEITC) can reactivate p53 mutant under in vitro and in vivo conditions, revealing a new mechanism of action for a dietary-related compound. PEITC exhibits growth-inhibitory activity in cells expressing p53 mutants with preferential activity toward p53(R175), one of the most frequent 'hotspot' mutations within the p53 sequence. Mechanistic studies revealed that PEITC induces apoptosis in a p53(R175) mutant-dependent manner by restoring p53 WT conformation and transactivation functions. Accordingly, in PEITC-treated cells the reactivated p53(R175) mutant induces apoptosis by activating canonical WT p53 targets, inducing a delay in S and G2/M phase, and by phosphorylating ATM/CHK2. Interestingly, the growth-inhibitory effects of PEITC depend on the redox state of the cell. Further, PEITC treatments render the p53(R175) mutant sensitive to degradation by the proteasome and autophagy in a concentration-dependent manner. PEITC-induced reactivation of p53(R175) and its subsequent sensitivity to the degradation pathways likely contribute to its anticancer activities. We further show that dietary supplementation of PEITC is able to reactivate WT activity in vivo as well, inhibiting tumor growth in xenograft mouse model. These findings provide the first example of mutant p53 reactivation by a dietary compound and have important implications for cancer prevention and therapy.


Subject(s)
Diet , Isothiocyanates/pharmacology , Mutation/genetics , Neoplasms/genetics , Neoplasms/pathology , Tumor Suppressor Protein p53/genetics , Apoptosis/drug effects , Ataxia Telangiectasia Mutated Proteins/metabolism , Autophagy/drug effects , Cell Cycle/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Checkpoint Kinase 2/metabolism , Histones/metabolism , Humans , Mutant Proteins/chemistry , Mutant Proteins/metabolism , Oxidation-Reduction , Proteasome Endopeptidase Complex/metabolism , Protein Conformation , Proteolysis/drug effects , Transcriptional Activation/genetics , Xenograft Model Antitumor Assays , Zinc/pharmacology
2.
Cell Death Dis ; 5: e1271, 2014 May 29.
Article in English | MEDLINE | ID: mdl-24874727

ABSTRACT

TP53, one of the most important oncosuppressors, is frequently mutated in cancer. Several p53 mutant proteins escape proteolytic degradation and are highly expressed in an aberrant conformation often acquiring pro-oncogenic activities that promote tumor progression and resistance to therapy. Therefore, it has been vastly proposed that reactivation of wild-type (wt) function(s) from mutant p53 (mutp53) may have therapeutic significance. We have previously reported that Zn(II) restores a folded conformation from mutp53 misfolding, rescuing wild-type (wt) p53/DNA-binding and transcription activities. However, whether Zn(II) affects mutp53 stability has never been investigated. Here we show that a novel Zn(II) compound induced mutp53 (R175H) protein degradation through autophagy, the proteolytic machinery specifically devoted to clearing misfolded proteins. Accordingly, pharmacological or genetic inhibition of autophagy prevented Zn(II)-mediated mutp53H175 degradation as well as the ability of the Zn(II) compound to restore wtp53 DNA-binding and transcription activity from this mutant. By contrast, inhibition of the proteasome failed to do so, suggesting that autophagy is the main route for p53H175 degradation. Mechanistically, Zn(II) restored the wtp53 ability to induce the expression of the p53 target gene DRAM (damage-regulated autophagy modulator), a key regulator of autophagy, leading to autophagic induction. Accordingly, inhibition of wtp53 transactivation by pifithrin-α (PFT-α) impaired both autophagy and mutp53H175 degradation induced by curcumin-based zinc compound (Zn(II)-curc). Viewed together, our results uncover a novel mechanism employed by Zn(II)-curc to reactivate mutp53H175, which involves, at least in part, induction of mutp53 degradation via wtp53-mediated autophagy.


Subject(s)
Autophagy/drug effects , Down-Regulation/drug effects , Tumor Suppressor Protein p53/metabolism , Zinc Compounds/pharmacology , Cell Line, Tumor , Curcumin/chemistry , HCT116 Cells , Humans , Microtubule-Associated Proteins/metabolism , Mutation , RNA Interference , RNA, Small Interfering/metabolism , Transcriptional Activation/drug effects , Tumor Suppressor Protein p53/antagonists & inhibitors , Tumor Suppressor Protein p53/genetics , Zinc Compounds/chemistry
3.
Nucleic Acids Res ; 29(20): 4114-24, 2001 Oct 15.
Article in English | MEDLINE | ID: mdl-11600700

ABSTRACT

Treatment of NIH 3T3 cells with trichostatin A (TSA), an inhibitor of histone deacetylase (HDAC), resulted in a dose-dependent increase in transcription from a rDNA reporter and from endogenous rRNA genes. Chromatin immunoprecipitation using anti-acetyl-histone H4 antibodies demonstrated a direct effect of TSA on the acetylation state of the ribosomal chromatin. TSA did not reverse inhibition of transcription from the rDNA reporter by retinoblastoma (Rb) protein, suggesting that the main mechanism by which Rb blocks rDNA transcription may not involve recruitment of deacetylases to rDNA chromatin. Overexpression of histone transacetylases p300, CBP and PCAF stimulated transcription in transfected NIH 3T3 cells. Recombinant p300, but not PCAF, stimulated rDNA transcription in vitro in the absence of nucleosomes, suggesting that the stimulation of rDNA transcription by TSA might have a chromatin-independent component. We found that the rDNA transcription factor UBF was acetylated in vivo. Finally, we also demonstrated the nucleolar localization of CBP. Our results suggest that the organization of ribosomal chromatin of higher eukaryotes is not static and that acetylation may be involved in affecting these dynamic changes directly through histone acetylation and/or through acetylation of UBF or one of the other components of rDNA transcription.


Subject(s)
DNA, Ribosomal/biosynthesis , Pol1 Transcription Initiation Complex Proteins , 3T3 Cells , Acetylation , Acetyltransferases/physiology , Animals , CREB-Binding Protein , Cell Nucleolus/chemistry , Chromatin/metabolism , DNA, Ribosomal/genetics , DNA-Binding Proteins/metabolism , Enzyme Inhibitors/pharmacology , Gene Expression Regulation , Genes, Reporter , Histone Deacetylase Inhibitors , Histones/metabolism , Hydroxamic Acids/pharmacology , Mice , Nuclear Proteins/analysis , Retinoblastoma Protein/physiology , Trans-Activators/analysis , Transcription Factors/metabolism , Transcription, Genetic/drug effects , Transfection
5.
J Biol Chem ; 275(27): 20853-60, 2000 Jul 07.
Article in English | MEDLINE | ID: mdl-10779504

ABSTRACT

The androgen receptor (AR) is a sequence-specific DNA-binding protein that plays a key role in prostate cancer cellular proliferation by dihydrotestosterone and the induction of secondary sexual characteristics. In this study we demonstrate that the AR can be modified by acetylation in vitro and in vivo. p300 and p300/cAMP-response element-binding protein acetylated the AR at a highly conserved lysine-rich motif carboxyl-terminal to the zinc finger DNA-binding domain. [(14)C]acetate-labeling experiments demonstrated that AR acetylation by p300 in cultured cells requires the same residues identified in vitro. Point mutation of the AR acetylation site (K632A/K633A) abrogated dihydrotestosterone-dependent transactivation of the AR in cultured cells. Mutation of the p300 CH3 region or the p300/cAMP-response element-binding protein histone acetylase domain reduced ligand-dependent AR function. The identification of the AR as a direct target of histone acetyltransferase co-activators has important implications for targeting inhibitors of AR function.


Subject(s)
Acetyltransferases/metabolism , Cell Cycle Proteins/metabolism , Nuclear Proteins/metabolism , Receptors, Androgen/metabolism , Saccharomyces cerevisiae Proteins , Trans-Activators/metabolism , Acetylation , Binding Sites , CREB-Binding Protein , Dihydrotestosterone/pharmacology , Enzyme Inhibitors/pharmacology , Genes, Reporter , Histone Acetyltransferases , Humans , Hydroxamic Acids/pharmacology , Lysine/genetics , Lysine/metabolism , Mutation , Peptide Fragments/metabolism , Protein Binding , Receptors, Androgen/genetics , Transcription Factors , Transcriptional Activation , Tumor Cells, Cultured , Zinc Fingers , p300-CBP Transcription Factors
6.
J Cell Physiol ; 181(2): 218-30, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10497301

ABSTRACT

p300 and CBP are highly related nuclear proteins, which have been implicated in transcriptional responses to disparate extracellular and intracellular signals. There are at least two very good reasons for which p300 and CBP have attracted the attention of the scientific world. First, they belong to an unique class of transcription co-activators possessing histone acetyltransferase activity and therefore have the potential to reveal basic aspects pertaining to regulation of chromatin structure. Second, p300 and CBP deliver essential functions in virtually all known cellular programs, including the decision to grow, to differentiate, or to commit suicide by apoptosis. Consistent with the complexity of these processes, a multitude of intracellular factors physically interact with p300 and CBP. Thus, the task of many investigations has been the understanding of how these proteins receive signals in the cells, what induces their recruitment in a given signal transduction pathway, and what determines the final outcome of their individual activity. This review will focus on mechanistic and theoretical questions pertaining to the mode of action of p300 and CBP posed by works performed in animal and in vitro model systems.


Subject(s)
Apoptosis/physiology , Nuclear Proteins/metabolism , Signal Transduction/physiology , Trans-Activators/metabolism , Animals , CREB-Binding Protein , Cell Differentiation , Humans , Nuclear Proteins/genetics , Trans-Activators/genetics
7.
Oncogene ; 16(16): 2103-14, 1998 Apr 23.
Article in English | MEDLINE | ID: mdl-9572491

ABSTRACT

We recently established transgenic animals (WAP-SV-T/t) carrying the early coding region of Simian Virus 40 (SV40) under the transcriptional control of the whey acidic milk protein promoter (WAP), which restricts the expression of the transgene to mammary gland epithelial cells (ME-cells). SV40 T/t-antigen synthesis causes premature mammary gland involution during late pregnancy by inducing apoptosis and leads to development of mammary tumors after the first lactation period in both p53 positive (WAP-SV-T/t) and p53 negative double transgenic animals (WAP-SV-T/t.p53-/-). The high apoptotic rate persists in all of the T/t-antigen positive breast tumor cells, as well as in established ME-tissue culture cell lines. ME-cells which spontaneously switch off the expression of the WAP-SV-T/t transgene do not undergo apoptosis. However, these cells again exhibit an extensive DNA fragmentation when SV40 T/t-antigen synthesis is reintroduced, which indicates that it is the expression of T/t antigen which is the critical factor for induction of apoptosis. In addition, we isolated several ME-cell lines from different breast tumors which have spontaneously lost the T/t-antigen yet remain maximally transformed. Strikingly, these cells contain a missense mutation of the p53 gene at codon 242 (p53(242)), which substitutes alanine for glycine. This mutation increases p53 stability and it reduces the transactivating function of p53, albeit without affecting the ability of the protein to interact with the DNA. This indicates that p53 missense mutations are selected for in breast tumors initially expressing T/t-antigen. Therefore, the p53(242) mutation is sufficient to maintain the transformed state after the ME-cells have switched off the WAP-SV-T/t transgene. Interestingly, the p53 minus state per se is not sufficient to induce ME-cell transformation since homozygous null mice for the p53 gene (p53-/-) fail to develop breast cancer.


Subject(s)
Antigens, Polyomavirus Transforming/metabolism , Apoptosis , Cell Transformation, Neoplastic , Mammary Neoplasms, Experimental/metabolism , Mutagenesis, Site-Directed , Tumor Suppressor Protein p53/genetics , Animals , Antigens, Polyomavirus Transforming/genetics , Cell Line , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/metabolism , Epithelial Cells/metabolism , Female , Mammary Glands, Animal , Mammary Neoplasms, Experimental/genetics , Mice , Mice, Transgenic , Pregnancy , Tumor Cells, Cultured , Tumor Suppressor Protein p53/metabolism
8.
Mol Cell ; 2(6): 869-75, 1998 Dec.
Article in English | MEDLINE | ID: mdl-9885574

ABSTRACT

PCAF histone acetylase is found in a complex with more than 20 associated polypeptides. Here we report cloning and characterization of the 400 kDa PCAF-associated factor referred to as PAF400. PAF400 is almost identical to TRRAP, which binds to c-Myc and E2F, and has significant sequence similarities to the ATM superfamily including FRAP, ATM, ATR, and the catalytic subunit of DNA-PK. Remarkably, PAF400 and FRAP share sequence similarity in broad regions that cover 80% of the entire PAF400 sequence. However, unlike the other members of the ATM superfamily, PAF400 is not a protein kinase as judged from the lack of kinase motif and autophosphorylation activity. We discuss the possibility that PAF400 may play a role in signaling of DNA damage to p53 by stimulation of p53 acetylation.


Subject(s)
Acetyltransferases/genetics , Protein Serine-Threonine Kinases , Proteins/genetics , Saccharomyces cerevisiae Proteins , Acetyltransferases/metabolism , Amino Acid Sequence , Ataxia Telangiectasia Mutated Proteins , Base Sequence , Cell Cycle Proteins , Cloning, Molecular , DNA, Complementary/chemistry , DNA, Complementary/genetics , DNA-Binding Proteins , HeLa Cells , Histone Acetyltransferases , Humans , Molecular Sequence Data , Phosphorylation , Proteins/metabolism , Sequence Alignment , Sequence Analysis, DNA , Sequence Homology, Amino Acid , Tumor Suppressor Proteins
9.
J Cell Biochem ; 66(3): 277-85, 1997 Sep 01.
Article in English | MEDLINE | ID: mdl-9257185

ABSTRACT

The conserved region 1 and the extreme N-terminus of adenoviral oncoprotein E1A are essential for transforming activity. They also play roles in the interaction of E1A with p300/CBP and pRb and are involved in both transactivation and repression of host gene expression. It was reported recently that p53-mediated transactivation is specifically repressed by E1A and that p53-induced apoptosis can be protected by pRb. In this report, we investigated the roles of pRb and p300 in the N-terminus of E1A-mediated transcriptional regulation. We demonstrate here that p300 and pRb have no effect on DBD.1-70 transactivation and that overexpression of p300 or pRb failed to relieve the repression by E1A. Repression of p53 transactivation requires both the extreme amino terminus and CR1 but not CR2. This repressive activity of E1A specifically correlates with E1A's ability to bind p300 and TBP. On the other hand, E1A inhibited the transactivation activity of a fusion construct containing the DNA binding domain of yeast Gal4 and the transactivation domain of p53. When p53 was contransfected with E1A, similar inhibition was found in Saos-2 cells that lack endogenous pRb and p53 activity. Introduction of pRb into Saos-2 cells did not affect p53 transcription activity. E1A-mediated repression can be relieved be overexpression of either p300, hTBP, or-TFIIB but cannot be released by overexpression of pocket proteins. Our data suggest that p300/CBP and TBP but not the pocket proteins, pRb, p107, and pRb2/p130 are functional targets of E1A in transcriptional regulation and that p53 transactivation requires the function of the p300/TBP/TFIIB complex, thus delineating a new pathway by which E1A may exert its transforming activity.


Subject(s)
Adenovirus E1A Proteins/metabolism , DNA-Binding Proteins/metabolism , Nuclear Proteins/metabolism , Trans-Activators , Transcription Factors/metabolism , Transcription, Genetic , Tumor Suppressor Protein p53/metabolism , Adenovirus E1A Proteins/genetics , Animals , Binding Sites , DNA-Binding Proteins/genetics , E1A-Associated p300 Protein , Mice , Peptide Fragments/genetics , Peptide Fragments/metabolism , Repressor Proteins/genetics , Repressor Proteins/metabolism , Retinoblastoma Protein/genetics , Retinoblastoma Protein/metabolism , TATA-Box Binding Protein , Transcription Factor TFIIB , Transcription Factors/genetics , Transcriptional Activation , Tumor Suppressor Protein p53/genetics
10.
Cell ; 89(7): 1175-84, 1997 Jun 27.
Article in English | MEDLINE | ID: mdl-9215639

ABSTRACT

The products of the p53 and CBP/p300 genes have been individually implicated in control of cell growth and regulation of transcription. p53 is known to act as a positive and negative regulator of gene expression. Here we show that p53, in both wild-type and mutant conformation, forms a specific protein complex with p300. However, in its wild-type but not mutant conformation, p53 inhibits a promoter containing the DNA-binding sequences for the transcription factor AP1, in a p300-dependent manner. p300 stimulates the transcriptional activity of p53 on p53-regulated promoters, and it enhances the responsiveness to a physiological upstream modulator of p53 function, ionizing radiation. A dominant negative form of p300 prevents transcriptional activation by p53, and it counteracts p53-mediated G1 arrest and apoptosis. The data implicate p300 as an important component of p53-signaling, thus providing new insight into the mechanisms of cellular proliferation.


Subject(s)
Nuclear Proteins/metabolism , Signal Transduction/physiology , Trans-Activators , Transcription Factors/metabolism , Tumor Suppressor Protein p53/metabolism , Animals , Apoptosis/physiology , Breast Neoplasms , CREB-Binding Protein , Cell Division/physiology , Cell Line , Chlorocebus aethiops , G1 Phase/physiology , Humans , Kidney/cytology , Mutagenesis/physiology , Nuclear Proteins/genetics , Transcription Factor AP-1/metabolism , Transcription Factors/genetics , Transcription, Genetic/physiology , Transfection , Tumor Cells, Cultured , Tumor Suppressor Protein p53/genetics
11.
EMBO J ; 16(2): 369-83, 1997 Jan 15.
Article in English | MEDLINE | ID: mdl-9029156

ABSTRACT

The nuclear phosphoprotein p300 is a new member of a family of 'co-activators' (which also includes the CREB binding protein CBP), that directly modulate transcription by interacting with components of the basal transcriptional machinery. Both p300 and CBP are targeted by the adenovirus E1A protein, and binding to p300 is required for E1A to inhibit terminal differentiation in both keratinocytes and myoblasts. Here we demonstrate that, in differentiating skeletal muscle cells, p300 physically interacts with the myogenic basic helix-loop-helix (bHLH) regulatory protein MyoD at its DNA binding sites. During muscle differentiation, MyoD plays a dual role: besides activating muscle-specific transcription, it induces permanent cell cycle arrest by up-regulating the cyclin-dependent kinase inhibitor p21. We show that p300 is involved in both these activities. Indeed, E1A mutants lacking the ability to bind p300 are greatly impaired in the repression of E-box-driven transcription, and p300 overexpression rescues the wild-type E1A-mediated repression. Moreover, p300 potentiates MyoD- and myogenin-dependent activation of transcription from E-box-containing reporter genes. We also provide evidence, obtained by microinjection of anti-p300 antibodies, that p300 is required for MyoD-dependent cell cycle arrest in either myogenic cells induced to differentiate or in MyoD-converted C3H10T1/2 fibroblasts, but is dispensable for maintenance of the postmitotic state of myotubes.


Subject(s)
Cell Cycle , Gene Expression Regulation, Developmental , Muscle Development , Muscle, Skeletal/growth & development , MyoD Protein/physiology , Nuclear Proteins/physiology , Trans-Activators , Transcription Factors/physiology , Animals , Blotting, Western , Cell Differentiation , DNA/metabolism , E1A-Associated p300 Protein , Helix-Loop-Helix Motifs , Mice , Microinjections , Myogenin/metabolism
12.
EMBO J ; 15(9): 2236-48, 1996 May 01.
Article in English | MEDLINE | ID: mdl-8641289

ABSTRACT

p300 is a nuclear phosphoprotein likely to be involved in the control of cell growth. Here we show that SV40 large T antigen (Tag) forms a specific complex with p300. In various Tag-expressing cell lines, the affinity of Tag for p300 was restricted to a newly identified unphosphorylated but ubiquitinated form of the protein. Further, Tag did not associate with p300 in an SV40 Tag-producing cell line (REV2) in which the original transformed phenotype (SV52) is reverted. Biochemical studies demonstrate that both the phosphorylation and the ubiquitination profile of p300 are altered in REV2 with respect to the wild-type fully transformed SV52 parental cells, wherein Tag-p300 complexes are readily detected. In contrast to Tag, the adenovirus early expression product E1a interacts with both phosphorylated and unphosphorylated forms of p300. In addition, when REV2 cells were infected with adenovirus, E1a-p300 complexes were detected, suggesting that the p300 expressed in REV2 has lost the affinity for Tag, but not for E1a. We then compared the ability of Tag and E1a to affect the transcription levels of the cAMP-responsive promoter (CRE), which is modulated in vivo by p300, in REV2 cells. We found that Tag repressed the CRE promoter in all of the cell lines in which Tag-p300 complexes were detected, but not in REV2 cells. In contrast, E1a efficiently inhibited CRE-directed transcription in this cell line. The data thus indicate that the different specificities exhibited by Tag and E1a towards the various forms of p300 are reflected in vivo as a difference in the ability of these viral oncoproteins to modulate the expression of CRE-containing genes.


Subject(s)
Adenovirus E1A Proteins/metabolism , Antigens, Polyomavirus Transforming/metabolism , Nuclear Proteins/metabolism , Trans-Activators/metabolism , Transcription Factors/metabolism , Animals , Cell Line , Chlorocebus aethiops , HeLa Cells , Humans , Phosphorylation , Protein Processing, Post-Translational , Ubiquitins/metabolism
13.
J Biol Chem ; 270(38): 22129-34, 1995 Sep 22.
Article in English | MEDLINE | ID: mdl-7673190

ABSTRACT

Angiotensin II (Ang-II) receptor engagement activates many immediate early response genes in both vascular smooth muscle cells and cardiomyocytes whether a hyperplastic or hypertrophic response is taking place. Although the signaling pathways stimulated by Ang-II in different cell lines have been widely characterized, the correlation between the generation of different second messengers and specific physiological responses remains relatively unexplored. In this study, we report how in both C2C12 quiescent myoblasts and differentiated myotubes Ang-II significantly stimulates AP1-driven transcription and c-Jun.c-Fos heterodimer DNA binding activity. Using a set of different protein kinase inhibitors, we could demonstrate that Ang-II-induced increase in AP1 binding is not mediated by the cAMP-dependent pathway and that both protein kinase C and tyrosine kinases are involved. The observation that in quiescent myoblasts Ang-II increase of AP1 binding and induction of DNA synthesis and, in differentiated myotubes, Ang-II stimulation of protein synthesis are abolished by the cysteine-derivative and glutathione precursor N-acetyl-L-cysteine strongly suggests a role for reactive oxygen intermediates in the intracellular transduction of Ang-II signals for immediate early gene induction, cell proliferation, and hypertrophic responses.


Subject(s)
Angiotensin II/physiology , DNA-Binding Proteins/metabolism , Muscles/physiology , Reactive Oxygen Species/metabolism , Transcription Factor AP-1/metabolism , 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine , Acetylcysteine/pharmacology , Animals , Base Sequence , Cell Differentiation/drug effects , Cell Division/drug effects , DNA/biosynthesis , Gene Expression/drug effects , Isoquinolines/pharmacology , Mice , Molecular Sequence Data , Oligodeoxyribonucleotides/chemistry , Piperazines/pharmacology , Protein Biosynthesis , Proto-Oncogene Proteins c-fos/metabolism , Proto-Oncogene Proteins c-jun/metabolism , RNA, Messenger/genetics , Signal Transduction
14.
Ann N Y Acad Sci ; 752: 394-405, 1995 Mar 27.
Article in English | MEDLINE | ID: mdl-7755283

ABSTRACT

Increasing evidence suggests that angiotensin II may act as a growth factor for several muscle cell types. Angiotensin II stimulation activates many immediate early response genes like c-Fos, c-Jun, c-Myc and Egr-1 in both vascular smooth muscle cells and cardiomyocytes, independently of whether a hyperplastic or hypertrophic response is taking place. In this study we report that angiotensin II significantly stimulates AP1-driven transcription in mouse skeletal muscle cells C2C12 stably transfected with a TRE-tk-CAT plasmid in a dose-dependent manner (peak stimulation at 10(-5) M of angiotensin II). Moreover, angiotensin II increases the binding of the AP1 complex to its DNA target in both quiescent C2C12 myoblasts and in differentiated C2C12 myotubes. Most of the TRE-bound complexes in both unstimulated and angiotensin II-treated cells consist of c-jun/c-fos heterodimers. Using a set of different protein kinase inhibitors, including HA1004, H7, tyrphostin, genistein and staurosporine, we could demonstrate that the angiotensin II-induced AP1 binding increase is not mediated by the cAMP-dependent pathway and that protein kinase C and tyrosine kinases are involved. Treatment of C2C12 cells with H2O2 induces a dose-dependent increase in c-jun/c-fos heterodimer binding, specifically reverted by the cysteine derivative and glutathione precursor N-acetyl-L-cysteine (NAC). The observation that the induction by angiotensin II of both the AP1 DNA binding activity and DNA synthesis in quiescent C2C12 myoblasts is abolished by NAC strongly suggests a role for reactive oxygen intermediates (ROIs) in the intracellular transduction of angiotensin II signals for immediate early gene induction and for cell proliferation.


Subject(s)
Angiotensin II/pharmacology , Gene Expression/drug effects , Muscle, Skeletal/physiology , Reactive Oxygen Species/metabolism , Signal Transduction , Signal Transduction/physiology , Animals , Antioxidants/pharmacology , Base Sequence , Cell Differentiation , Cell Line , Genes, Immediate-Early/drug effects , Heart/drug effects , Mice , Molecular Sequence Data , Muscle, Skeletal/cytology , Muscle, Skeletal/drug effects , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/metabolism , Myocardium/metabolism , Oligodeoxyribonucleotides , Protein Kinase Inhibitors , Protein Kinases/metabolism , Proto-Oncogene Proteins c-fos/biosynthesis , Proto-Oncogene Proteins c-jun/biosynthesis , Recombinant Fusion Proteins/biosynthesis , Signal Transduction/drug effects , Transcription Factor AP-1/metabolism , Transfection
15.
J Hepatol ; 22(1 Suppl): 14-20, 1995.
Article in English | MEDLINE | ID: mdl-7602067

ABSTRACT

The mechanisms by which pX, the transactivator of the hepatitis B virus (HBV), exerts its effects on transcription of viral and cellular genes and affects cell-growth regulation have not yet been fully defined. Previous reports suggested the possibility of a direct interaction of pX, which lacks intrinsic DNA-binding activity, with components of the cellular transcription machinery. More recent investigations support the hypothesis that pX might activate cellular kinases involved in transcriptional regulation and growth control. We characterized the mechanisms of AP-1 transcription factor activation by pX and, in particular, the role of cellular proteins involved in the intracellular signal transduction of growth-factor receptors. The observation that the overexpression of c-fos and c-jun in the cells results in a clear augmentation of the effects of pX on TRE-directed transcription and the induction of the DNA-binding activity of c-jun/c-fos heterodimers by AP1-depleted nuclear extracts from pX-expressing cells strongly supports the involvement of post-translational modifications. In both HeLa and undifferentiated F9 cells, pX was able to increase the activity of exogenous transfected c-jun but not of c-jun mutants bearing mutations in the serine residues located in the amino-terminal transcriptional activation domain. Moreover, by use of Ha-ras and Raf-1 dominant negative mutants, we show that both Ha-ras and Raf-1 are required for pX-induced activation of c-jun transcriptional activity.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Genes, jun/physiology , Genes, pX/physiology , Hepatitis B virus/genetics , Signal Transduction/physiology , Transcriptional Activation , Animals , Humans , Signal Transduction/genetics , Transcription Factors/physiology , Transcription, Genetic
16.
Oncogene ; 9(10): 2837-43, 1994 Oct.
Article in English | MEDLINE | ID: mdl-8084589

ABSTRACT

The mechanisms by which pX, the transactivator of the Hepatitis B Virus (HBV), exerts its effects on transcription of viral and cellular genes have not yet been fully clarified. While previous reports suggested the possibility of a direct interaction of pX, which lacks intrinsic DNA-binding activity, with components of the cellular transcription machinery, more recent investigations support the hypothesis that pX might activate cellular kinases involved in transcriptional regulation and growth control. We analysed the mechanisms of c-Jun transcription factor activation by pX and in particular the role of cellular proteins involved in the transduction of mitogenic signals (namely Ha-Ras and Raf-1). In both HeLa and undifferentiated F9 cells pX was able to increase the activity of exogenous transfected c-Jun but not of c-Jun proteins bearing mutations in the serine residues located in the amino-terminal transcriptional activation domain. We show by use of Ha-Ras and Raf-1 dominant negative mutants that both Ha-Ras and Raf-1 are required for pX-induced activation of c-Jun transcriptional activity. In addition we show that pX is able to cooperate with Raf-1 in c-Jun activation. Our results are consistent with the hypothesis that at least one site of action of pX is peripheral and is located upstream of the Ras genes products.


Subject(s)
Hepatitis B virus/genetics , Oncogene Protein p21(ras)/metabolism , Proto-Oncogene Proteins c-jun/genetics , Retroviridae Proteins, Oncogenic/metabolism , Trans-Activators/metabolism , Transcriptional Activation , Cell Line , Chloramphenicol O-Acetyltransferase/genetics , Genes, ras , HeLa Cells , Humans , Oncogene Proteins v-raf , Signal Transduction , Viral Regulatory and Accessory Proteins
17.
Ann Ital Med Int ; 9(3): 160-5, 1994.
Article in English | MEDLINE | ID: mdl-7946893

ABSTRACT

Myocardial hypertrophy is an adaptive response of the heart to several pathological situations aimed at maintaining adequate cardiac contractile function. This process is characterized by complex qualitative and quantitative changes of both cardiomyocytes and nonmyocyte cardiac cells. The initial stimulus inducing these cellular responses is parietal stretch subsequent to either a pressure or volume overload. Many substances locally produced and acting in a paracrine-autocrine fashion are involved in the response to stretch by cardiac cells. The stretch, and, similarly, various growth factors (i.e. angiotensin II. endothelins, transforming growth factor beta, fibroblast growth factors), are able to modulate the expression of several protooncogenes in the cells of the myocardium, and these events are linked to the development of cardiac hypertrophy. Major goals of future research will include the detection of the molecular mechanisms enabling the cardiomyocyte, a terminally differentiated muscle cell, to respond to a mitogenic stimulus with hypertrophic rather than hyperplastic growth, as well as the identification of drugs able to block the evolution of hypertrophy to heart failure.


Subject(s)
Cardiomegaly/genetics , Adult , Animals , Cardiomegaly/pathology , Cell Differentiation , Cell Division , Gene Expression , Humans , In Vitro Techniques , Infant, Newborn , Mice , Myocardium/cytology , Myocardium/pathology , Proto-Oncogenes/genetics , Rats , Regeneration , Transcription, Genetic
18.
J Virol ; 68(5): 3138-44, 1994 May.
Article in English | MEDLINE | ID: mdl-8151779

ABSTRACT

The simian virus 40 (SV40) large-T antigen is essential for SV40 DNA replication and for late viral gene expression, but the role of the SV40 small-t antigen in these processes is still unclear. We have previously demonstrated that small t inhibits SV40 DNA replication in vitro. In this study, we investigated the effect of small t on SV40 replication in cultured cells. CV1 monkey cell infection experiments indicated that mutant viruses that lack small t replicate less efficiently than the wild-type virus. We next microinjected CV1 cells with SV40 DNA with and without purified small-t protein and analyzed viral DNA replication efficiency by Southern blotting. Replication of either wild-type SV40 or small-t deletion mutant DNA was increased three- to fivefold in cells coinjected with purified small t. Thus, in contrast to our in vitro observation, small t stimulated viral DNA replication in vivo. This result suggests that small t has cellular effects that are not detectable in a reconstituted in vitro replication system. We also found that small t stimulated progression of permissive monkey cells--but not of nonpermissive rodent cells--from G0-G1 to the S phase of the cell cycle, possibly leading to an optimal intracellular environment for viral replication.


Subject(s)
Antigens, Viral, Tumor/pharmacology , DNA Replication/drug effects , DNA, Viral/biosynthesis , Simian virus 40/growth & development , Virus Replication , Animals , Antigens, Viral, Tumor/genetics , Antigens, Viral, Tumor/metabolism , Cell Cycle/drug effects , Cells, Cultured , Chlorocebus aethiops , Mice , Microinjections , Mutation , Phosphorylation , Protein Kinases/metabolism , Simian virus 40/immunology
19.
Mol Cell Biol ; 14(2): 989-98, 1994 Feb.
Article in English | MEDLINE | ID: mdl-7507209

ABSTRACT

The hepatitis B virus (HBV) X protein (pX) is capable of activating transcription regulated by viral and cellular promoters containing binding sites for different transcription factors, including AP1. In this study we have analyzed the mechanisms of AP1 induction by pX. The hepatitis B virus transactivator was able to activate TRE (12-O-tetradecanoylphorbol-13-acetate response element)-directed transcription in different cell lines, including HepG2, HeLa, CV1, and PLC/PRF/5 cells. pX-induced AP1 activation in HepG2 cells was associated with an increase in the DNA-binding activity of c-Jun/c-Fos heterodimers, which was not dependent either on an increase in the overall amount of c-Fos and c-Jun proteins in the cells or on formation of dimers between pX and the two proteins, thus suggesting the involvement of posttranslational modifications of the transcription factor. The observation that the overexpression of c-Jun and c-Fos in the cells results in a strong augmentation of the effect of pX on TRE-directed transcription is additional evidence indicating the involvement of posttranscriptional modifications of c-Jun/c-Fos heterodimers. The increased AP1 binding observed in the presence of pX was unaffected by the protein kinase C inhibitors calphostin C and sphingosine and by the protein kinase A inhibitor HA1004, while it was almost completely blocked by staurosporine, a potent and nonspecific protein kinase inhibitor, suggesting that protein kinase C- and A-independent phosphorylation events might play a role in the phenomenon. The ability of pX also to increase TRE-directed transcription in cell lines in which AP1-binding activity is not increased (i.e., HeLa, CV1, and PLC/PRF/5 cells) suggests that pX can activate canonical TRE sites by different mechanisms as well.


Subject(s)
DNA-Binding Proteins/metabolism , Hepatitis B virus/metabolism , Naphthalenes , Protein Kinases/metabolism , Proto-Oncogene Proteins c-fos/metabolism , Proto-Oncogene Proteins c-jun/metabolism , Sulfonamides , Trans-Activators/metabolism , Transcriptional Activation , Alkaloids/pharmacology , Animals , Base Sequence , Binding Sites , Cell Line , Cell Nucleus/metabolism , Chloramphenicol O-Acetyltransferase/biosynthesis , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , HeLa Cells , Humans , Isoquinolines/pharmacology , Kinetics , Macromolecular Substances , Molecular Sequence Data , Oligodeoxyribonucleotides/metabolism , Phosphorylation , Polycyclic Compounds/pharmacology , Protein Kinase C/antagonists & inhibitors , Proto-Oncogene Proteins c-fos/biosynthesis , Proto-Oncogene Proteins c-jun/biosynthesis , Sphingosine/pharmacology , Staurosporine , Tetradecanoylphorbol Acetate/pharmacology , Transcription, Genetic/drug effects , Transcriptional Activation/drug effects , Transfection , Tumor Cells, Cultured , Vaccinia virus/genetics , Viral Regulatory and Accessory Proteins
20.
Oncogene ; 8(6): 1567-74, 1993 Jun.
Article in English | MEDLINE | ID: mdl-8502480

ABSTRACT

The hepatitis B virus (HBV) X protein (pX) stimulates transcription regulated by cis-acting elements that control many viral and cellular genes, including the c-myc and the c-fos proto-oncogenes. Using several c-fos promoter deletion mutants, we found the serum-responsive element (SRE) located at -315, the modified TPA-responsive element located at -296 (fos-AP-1 binding site, FAP) and the region spanning from nucleotide -220 to -120, which contains an NF1-like site and several stretches of sequence homologous to the AP-2 consensus binding sites, to be responsive to pX. pX does not modify the pattern of the retarded complexes bound to the SRE/FAP region which, in our system, appears to be occupied by SRE-binding factors. The activation of the SRE does not involve complex formation between SRE-binding factors and pX, it is not associated with an increase in serum response factor binding to the SRE and it does not determine changes in SRE mobility-shift pattern.


Subject(s)
Genes, fos , Hepatitis B virus/genetics , Promoter Regions, Genetic , Regulatory Sequences, Nucleic Acid , Trans-Activators/metabolism , Transcriptional Activation , Animals , Base Sequence , Cell Nucleus/metabolism , Chloramphenicol O-Acetyltransferase/genetics , Chloramphenicol O-Acetyltransferase/metabolism , Gene Expression Regulation, Viral , HeLa Cells , Humans , Molecular Sequence Data , Oligodeoxyribonucleotides , Plasmids , Protein Kinases/metabolism , Restriction Mapping , Transcription, Genetic , Transfection , Vero Cells , Viral Regulatory and Accessory Proteins
SELECTION OF CITATIONS
SEARCH DETAIL
...